



Inhibition of Xanthine Oxidase by catechins from tea (*Camellia sinensis*)

By: Jean Pieter Aucamp

**Submitted in partial fulfilment of the requirements
for the degree Master of Science**

in the Faculty of Natural and Agricultural Sciences

Department of Biochemistry

University of Pretoria

Pretoria

September 2000

Acknowledgments

I acknowledge with gratitude the following people and institutions:

The National Research Foundation of South Africa for financial assistance.

The Tea Council of Southern Africa and the Tea Research Foundation of Central Africa for partial funding.

Dr. Y. Hara of Mitsui Norin in Japan for provision of reagents.

The Department of Biochemistry of the University of Pretoria for granting me the opportunity to undertake this study.

Doctors Z. Apostolides and A. Gaspar as well as Professor A. Neitz for their academic input, support and guidance during my studies and assistance with the completion of this thesis.

My family and friends for their moral support and encouragement.



Table of contents **page no**

List of Tables i
List of Figures..... ii
List of abbreviations..... vi

Chapter 1: Introduction

1 The importance of natural products 1
2 Natural products contributing to quality of tea 3
3 Bioactive natural products in tea 5
 3.1 *Identification of the bioactive tea compounds*..... 5
 3.2 *Intrinsic properties of polyphenols*..... 6
 3.3 *Structural Principles for Radical Scavenging by Flavonoids*..... 8
 3.4 *Antioxidant activity of the catechins and catechin gallate esters*..... 11
 3.5 *Properties of methylxanthines*..... 12
4 Bioactivities documented for tea components..... 12
 4.1 *Tea polyphenols and cancer* 12
 4.2 *Inhibition of other enzymes* 16
 4.3 *Prophylactic properties of tea methylxanthines*..... 17
5 Analytical methods in natural product chemistry..... 17
6 Objectives of the study 19
 6.1 *The detection and quantification of important constituents in tea leaf*..... 19
 6.2 *To study the inhibition of Xanthine Oxidase by tea polyphenols* 20
7 Aims of study 22
8 Hypotheses..... 23

Chapter 2: Development of a MEKC method for analyzing tea compounds

1 Introduction..... 24
2 Materials and Methods..... 30
 2.1 *Strategy for optimization of a MEKC method* 30
 2.2 *Instrumentation*..... 32
 2.3 *Reagents* 32
 2.4 *Analytical conditions*..... 33
 2.5 *Preparation of samples and standard*..... 33
3 Results and Discussion..... 35
 3.1 *Influence of pH*..... 37
 3.2 *Influence of SDS concentration* 39
 3.3 *Influence of phosphate concentration*..... 42
 3.4 *Influence of organic modifier concentration*..... 44



3.5	<i>Influence of applied voltage</i>	48
3.6	<i>Suitability of internal standard</i>	49
3.7	<i>Regression Analysis</i>	50
3.8	<i>Validation of analytical procedure</i>	50
3.9	<i>Optimum condition</i>	56
4	Conclusion	57

Chapter 3: *In vitro* and *in silico* inhibition studies on Xanthine Oxidase with tea polyphenols

1	Introduction.....	58
2	Materials and Method	68
2.1	<i>Materials</i>	68
2.2	<i>Xanthine Oxidase assay</i>	68
2.3	<i>Molecular modeling of XO inhibitors</i>	69
3	Results and Discussion.....	69
3.1	<i>Inhibition of XO with tea polyphenols</i>	69
3.2	<i>Model for structurally similar XO inhibitors</i>	72
3.3	<i>Factors influencing apparent K_i values</i>	81
3.4	<i>Structural requirements for modulating K_i/K_I ratios</i>	85
4	Conclusion	88

Chapter 4: *In vivo* analysis of Xanthine Oxidase substrates and products with CE

1	Introduction.....	90
2	Materials and Methods.....	96
2.1	<i>Experimental strategy</i>	96
2.2	<i>Instrumentation</i>	96
2.3	<i>Reagents</i>	97
2.4	<i>Analytical conditions</i>	97
2.5	<i>Preparation of samples and standard</i>	98
2.6	<i>Preliminary inhibition experiments</i>	99
3	Results and Discussion.....	99
3.1	<i>Comparison of the two methods</i>	100
3.2	<i>Serum and Urine Samples</i>	107
4	Conclusion	113

Chapter 5: *In vivo* Xanthine Oxidase inhibition studies

1	Introduction.....	115
2	Materials and Method	116
2.1	<i>Experimental Strategy</i>	116
2.2	<i>Animals</i>	117



2.3	<i>Materials</i>	118
2.4	<i>Test drugs</i>	118
2.5	<i>Treatment protocol</i>	118
2.6	<i>Measurement of analytes in urine and serum samples</i>	119
2.7	<i>Statistical analysis</i>	119
3	Results	119
3.1	<i>Hypouricemic effects of inhibitors on hyperuricemic rats</i>	119
3.2	<i>Hypouricemic effects of inhibitors in normal rats</i>	123
3.3	<i>Lack of inhibition with catechins</i>	124
4	Conclusion	129
	Chapter 6: Concluding discussion	131
	Summary	140
	Opsomming	144
	References	147

List of Tables

Table 1.1 A list of selected polyphenols with their free hydroxyl group distribution and antioxidant potentials.

Table 2.1 The importance of pH on the selection of MEKC and CZE buffer conditions for flavonoids and flavonoid glycosides separation methods.

Table 2.2 Limits of detection and quantification values, linear limits and regression coefficients of all analytes.

Table 2.3 Statistical evaluation of intra-day and inter-day data to determine the variation in the migration times.

Table 2.4 Typical concentrations of analytes found in dried fresh leaf (green tea), black tea and bottled tea.

Table 3.1 Summary of the kinetic data of the tested polyphenols.

Table 4.1 The calculated charges and mass:charge ratios from pKa values as well as the calculated electrophoretic mobilities for the analytes using the CZE method.

Table 4.2 Comparison of the MEKC and CZE methods, focusing on the column efficiency, peak symmetries and limits of detection for the respective methods.

Table 4.3 A summary of the calibration curve data for the analytes with the CZE method.

Table 5.1 The catechin contents in Polyphenon-70S (TPM in this study).

List of Figures

Figure 1.1 A schematic representation of the inter-relationship between the most important flavonoid sub-groups.

Figure 1.2 Xanthine oxidase catalyzes an oxidation-reduction reaction.

Figure 2.1 Scheme for the experimental strategy followed to optimize a MEKC method to analyze tea catechins.

Figure 2.2 Chemical structures of organoleptically important compounds in tea and the pNP internal standard.

Figure 2.3 Influence of pH on the capacity factors of compounds.

Figure 2.4 Influence of SDS concentration on the capacity factors of compounds.

Figure 2.5 Linear dependence of analyte capacity factors on the surfactant concentration.

Figure 2.6 The effect of the surfactant concentration on the retention window required for separation of analytes.

Figure 2.7 The effects of increased surfactant concentration on the column efficiency as calculated with the caffeine, EC, and pNP peaks.

Figure 2.8 Influence of background electrolyte concentration on the capacity factors of compounds.

Figure 2.9 Influence of organic modifier on the capacity factors of compounds.

Figure 2.10 The linear quantitative relationships found for **A**: $1/k'$ vs. methanol concentration and **B**: $R_{m,mc}$ vs. methanol concentration.

Figure 2.11 The effects of the methanol concentration on the retention window required for separating the analytes.

Figure 2.12 The influence of the 1-propanol concentration on the migration times of the analytes.

Figure 2.13 The analysis of a 2% (w/v) water extract of green tea with acetonitrile as organic modifier.

Figure 2.14 The influence of applied voltage on the capacity ratios of the analytes.

Figure 2.15 **A:** Separation of standard mix. **B:** Separation of fresh leaf sample 1% (w/v) solution 5 times diluted. **C:** Separation of black tea sample 1% (w/v) solution 3 times diluted.

Figure 2.16 **A:** Separation of standard mix. **B:** Separation of undiluted canned tea sample.

Figure 2.17 The determination of the optimum capacity factor.

Figure 3.1 Structures of the variant forms of molydopterin.

Figure 3.2 A schematic presentation of the ping-pong catalytic action of xanthine oxidase.

Figure 3.3 The structure of the molybdenum coordination complex.

Figure 3.4 Amino acid sequence alignment of Mop (Aldehyde Oxido-reductase) with Xanthine Dehydrogenases.

Figure 3.5 Molecular structure of aldehyde oxido-reductase and ligands.

Figure 3.6 The reductive half-cycle of the hydroxylation reaction of aldehyde oxido-reductase and xanthine oxidase.

Figure 3.7 The Lineweaver-Burk plot for the inhibition of xanthine oxidase by (-)-EGCg with xanthine as substrate.

Figure 3.8 The linear secondary plots of the inhibitor (-)-ECg.

Figure 3.9 The non-linear secondary plot of the inhibitor kaempferol.

Figure 3.10 The three dimensional structures of the XO substrates, products and their inhibitory analogues.

Figure 3.11 A possible model by which the tea polyphenols as well as XO substrate and product analogues exert their inhibitory effects.

Figure 3.12 Polyphenols may have two regions that are important in defining their inhibitory effects on XO.

Figure 3.13 Structural similarities between synthetic pyrazolo-pyrimidines XO inhibitors and tea polyphenols.

Figure 3.14 The substrate binding cavity of aldehyde oxido-reductase.

Figure 3.15 A schematic presentation of one way how the polyphenol may fit into the funnel-shaped active center of XO.

Figure 4.1 Scheme of the biochemical regulation of uric acid levels in humans and rats as well as the chemical oxidation of uric acid.

Figure 4.2 A: Xanthine oxidase catalyzes the conversion of allopurinol to oxypurinol.
B: The chemical structures of other compounds of interest in the analysis of rat serum.

Figure 4.3 The separation of XO substrates, products and inhibitors with **A:** the MEKC method and **B:** the CZE method.

Figure 4.4 The linear relationship between the mobilities and charge/mass ratios of the different analytes in CZE mode.

Figure 4.5 The influence of pH on the migration times of the analytes in CZE mode.

Figure 4.6 A: Analysis of control rat urine (untreated) separated with the CZE conditions. **B:** Analysis of rat urine from rats orally dosed 20 mg/kg allopurinol.

Figure 4.7 A: Analysis of control rat serum (untreated). **B:** Analysis of rat serum from rats orally dosed 20 mg/kg allopurinol.

Figure 4.8 A: Analysis of control rat serum (untreated). **B:** Analysis of rat serum from rats subcutaneously dosed 250 mg/kg potassium oxonate.



Figure 4.9 **A:** Analysis of control rat urine (untreated). **B:** Analysis of rat urine from rats subcutaneously dosed 250 mg/kg potassium oxonate.

Figure 4.10 Comparison of UV spectra of analytes (**A:** 9-methylxanthine, **B:** uric acid, **C:** oxypurinol, and **D:** xanthine) from rat serum or urine with that of pure standards.

Figure 5.1 The hyperuricemic effect of 250 mg/kg potassium oxonate on serum and urine urate levels of normal rats.

Figure 5.2 **A** Time course of the effect of allopurinol on serum uric acid levels of hyperuricemic rats. **B:** Time course of the effect of EGCg on serum uric acid levels. **C:** Time course of the effect of TPM on serum uric acid levels.

Figure 5.3 The effect of different doses allopurinol, (-)-EGCg and TPM on the serum urate and xanthine levels in hyperuricemic rats.

Figure 5.4 The total amount of xanthine and uric acid 4h after treatment of hyperuricemic animals was conserved.

Figure 5.5 The serum levels of oxypurinol increased with an increase in the allopurinol dosage concentration.

Figure 5.6 **A** Time course of the effect of allopurinol on serum uric acid levels of normal rats. **B:** Time course of the effect of EGCg on serum uric acid levels. **C:** Time course of the effect of TPM on serum uric acid levels.



List of abbreviations

ACE	Angiotensin converting enzyme
AIDS	Acquired Immunodeficiency Syndrome
AOR	Aldehyde oxido-reductase
BGE	Back ground electrolyte
C	(+)-catechin
CE	Capillary electrophoresis
CMC	critical micellar concentration
CTAB	Cetyltrimethylammonium boromide
CTC	cut, tear and curl
CYP	Cytochrome P-450 gene notation
CZE	Capillary zone electrophoresis
DMSO	dimethylsulfoxide
DNA	deoxyribonucleic acid
EC	(-)-epicatechin
E.C.	Enzyme Commission
ECg	(-)-epicatechin gallate
EGC	(-)-epigallocatechin
EGCg	(-)-epigallocatechin gallate
EGF	Epidermal growth factor
EOF	Electro-osmotic flow
FAD	Flavin adenine dinucleotide
GC	(+)-galocatechin
GC	Gas chromatography
GCg	(-)-galocatechin gallate
GTP	Green tea polyphenols
GSH	Reduced glutathione
HETE	hydroxyeicosatetraenoic acid
HGPRT	hypoxanthine-guanine phosphoribosyl transferase
HIV	Human immunodeficiency virus
HPCCC	High performance centrifugal counter current chromatography
HPLC	High performance liquid chromatography



HRMS	High resolution mass spectrometry
i.g.	intragastrically
IMP	inosine monophosphate
ITP	Isotachophoresis
LC	Liquid chromatography
LOD	Limit of detection
LOQ	Limit of quantification
MAPK	Mitogen activated protein kinase
MEKC	Micellar electrokinetic chromatography
MMP	Matrix-metallo proteinases
Moco	molybdenum cofactor
mRNA	messenger ribonucleic acid
MT	Migration time
NAD ⁺	oxidized nicotinamide adenine dinucleotide
NADH	reduced nicotinamide adenine dinucleotide
NNK	4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
ORM	Overlapping resolution mapping
P450	Cytochrome P-450
pBR	phosphorylated retinoblastom protein
PPRP	phosphoribosylpyrophosphate
PKC	Protein kinase C
pNP	<i>p</i> -nitrophenol
RP-HPLC	Reversed phase high performance liquid chromatography
RSD	Relative standard deviation
RNA	ribonucleic acid
SC	Sodium cholate
S.D.	Standard deviation
SDS	Sodium dodecyl sulfate
SEM	standard error of the mean
TEAC	Trolox-Equivalent Antioxidant Capacity
TNF α	Tumor necrosis factor α



TPA	12-O-tetradecanoylphorbol-13-acetate
TPM	tea polyphenol mix
UV	Ultraviolet
UVB	Ultraviolet B radiation
XDH	Xanthine dehydrogenase
XO	Xanthine oxidase
γ -CD	gamma-cyclodextrin